- Home
- HUBS vs BMRN Comparison
HUBS vs BMRN Comparison
Compare HUBS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUBS | BMRN |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 12.3B |
| IPO Year | 2014 | 1999 |
Fundamental Metrics
Financial Performance| Metric | HUBS | BMRN |
|---|---|---|
| Price | $236.85 | $56.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 35 | 28 |
| Target Price | ★ $248.77 | $91.59 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 11-04-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 855.56 | N/A |
| EPS | ★ 1.47 | 0.77 |
| Revenue | $375,612,000.00 | ★ $1,313,646,000.00 |
| Revenue This Year | $17.65 | $21.45 |
| Revenue Next Year | $13.91 | $14.55 |
| P/E Ratio | $154.97 | ★ $71.60 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $169.63 | $49.26 |
| 52 Week High | $497.96 | $70.98 |
Technical Indicators
Market Signals| Indicator | HUBS | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 36.03 |
| Support Level | $229.01 | $53.61 |
| Resistance Level | $256.19 | $57.95 |
| Average True Range (ATR) | 10.14 | 1.38 |
| MACD | 2.37 | -0.16 |
| Stochastic Oscillator | 85.88 | 32.85 |
Price Performance
Historical ComparisonAbout HUBS HubSpot Inc.
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.